Comparing macular thickness and visual acuity responses retinal vein occlusion versus diabetic macular edema following anti vascular endothelial growth factor therapy: A retrospective analysis

: Vascular growth factor associates Retinal vein occlusion (RVO) and Diabetic Macular Edema (DME). A retrospective analysis using database from a tertiary hospital. : The study aims to evaluate effects of anti-vascular growth factor therapy on patients Diabetic Macular Edema with and retinal vein occlusion, : This study conducted between December 2022 and June 2023 where 30 patients diagnosed with Diabetic macular edema (DME, n=15) or Retinal vein occlusion (RVO, n=15) receiving anti-VEGF were examined. This focused on changes in best corrected visual acuity, central macular thickness and predictors over a period of three months. : Retinal Vein Occlusion (RVO) patients exhibited a more significant improvement in Best Corrected Visual Acuity (BCVA) compared to Diabetic Macular Edema (DME) (25 vs. 10 letters, p = 0.006) after three months. The change in Central Macular Thickness (CMT) also favored RVO (100µm) over DME (40µm, p = 0.012). Final BCVA median was 70 for DME and 65 for RVO (p = 0.461). Considering initial BCVA and CMT, RVO predicted better visual enhancement than DME. : RVO exhibited major BCVA improvement at three months with Anti-Vascular Endothelial Growth Factor. Final vision was indistinguishable for DME and RVO. Anti VEGF stabilizes DME vision. Despite the improvement, early RVO diagnosis and treatment may enhance final vision.